Rheumatology International

, Volume 33, Issue 7, pp 1713–1719 | Cite as

Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence

  • Arnd GieseEmail author
  • Mustafa Kurucay
  • Levent Kilic
  • Ahmet Örnek
  • Süleyman Nahit Şendur
  • Elke Lainka
  • Bernhard Ferdinand Henning
Original Article


We assessed quality of life (QOL) and disease activity in patients with Familial Mediterranean fever (FMF) of Turkish ancestry living in Germany or Turkey and conducted a correlation with FMF disease activity. 40 FMF patients in Turkey (TR), 40 FMF patients in Germany (G) and 40 healthy controls in Germany (C) were included. QOL was evaluated with the short form of the World Health Organisation Quality of Life scale (WHOQOL-BREF). FMF disease activity was examined with the Pras score. Mean age was TR 30.5 ± 10.6, G 35.2 ± 10.2, C 34.6 ± 10.7. Of the 120 participants, 77 were female. FMF patients in TR and G had a significantly decreased QOL physical health domain compared to controls (TR 59.7 ± 18.8, G 60.4 ± 19.4, C 76.5 ± 14.6). Turkish FMF patients had a lower QOL environment domain compared to controls (TR 62.3 ± 17.5, G 69.7 ± 16.5, C 72.3 ± 13.5). In the other QOL domains, no significant differences were found. The differences in QOL were robust to a regression analysis. No significant correlation between QOL and FMF disease activity was found. German FMF patients had longer duration of disease, younger age at onset and longer delay from disease onset to colchicine treatment. A total of 5 of 40 German FMF patients were not taking colchicine (TR:0). Erythrocyte sedimentation rate was lowest in TR with significant difference between TR and G as well as G and C (TR 13.2 ± 10.3, G 27.8 ± 19.4, C 16.3 ± 12.8 mm/h). C-reactive protein did not differ between TR and G. FMF has an important impact on QOL physical health domain. No correlation between FMF disease activity and the WHOQOL-BREF could be found.


Familial Mediterranean fever Quality of life Turkey Germany Severity of illness index Adult 



We are indebted to Dr. Atilla Cintosun, Herne, for his assistance in patient recruitment. Part of the study was supported by the German Ministry of Education and Research (BMBF 01GM08104).

Conflict of interest

There are no financial or other relationships that could lead to a conflict of interest.


  1. 1.
    Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351:659–664PubMedCrossRefGoogle Scholar
  2. 2.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of Familial Mediterranean fever. Arthr Rheum 40(10):1879–1885CrossRefGoogle Scholar
  3. 3.
    Consortium TIF (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause Familial Mediterranean fever. Cell 90:797–807CrossRefGoogle Scholar
  4. 4.
    Consortium FF (1997) A candidate gene for Familial Mediterranean fever. Nat Genet 17(1):25–31CrossRefGoogle Scholar
  5. 5.
    Chae J, Wood G, Masters S, Richard K, Park G, Smith B, Kastner D (2006) The B30.2 domain of pyrin, the Familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 103(26):9982–9987PubMedCrossRefGoogle Scholar
  6. 6.
    Livneh A, Langevitz P (2000) Diagnostic and treatment concerns in Familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 14(3):477–498. doi: 10.1053/berh.2000.0089 PubMedCrossRefGoogle Scholar
  7. 7.
    Gafni J, Ravid M, Sohar E (1968) The role of amyloidosis in Familial Mediterranean fever. A population study. Isr J Med Sci 4(5):995–999PubMedGoogle Scholar
  8. 8.
    Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, Langevitz P (1997) Quality of life of patients with Familial Mediterranean fever. Clin Exp Rheumatol 15(4):355–360PubMedGoogle Scholar
  9. 9.
    Aksentievitz I, Kastner D, Consortium TIF (1997) Microsatellite haplotypes and MEFV mutations: exploring the genealogy of FMF. In: Sohar E, Gafni J, Pras M (eds) 1st international conference on FMF, Jerusalem, 1997. Freund, Tel Aviv, pp 246–251Google Scholar
  10. 10.
    İçduygu A, Sert D (2009) Country profile Turkey. Hamburg Institute of International Economics. Accessed 16 Mar 2012
  11. 11.
    Manco U (2008) Turks in Europe: from a garbled image to the complexity of migrant social reality. Accessed 16 Mar 2012
  12. 12.
    Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, Yalçinkaya F, Ozen S, Majeed H, Ozdogan H, Kastner D, Booth D, Ben-Chetrit E, Pugnère D, Michelon C, Séguret F, Gershoni-Baruch R, Fever ISGfP-GCiFM (2007) Country as the primary risk factor for renal amyloidosis in Familial Mediterranean fever. Arthr Rheum 56(5):1706–1712CrossRefGoogle Scholar
  13. 13.
    Ozen S, Aktay N, Lainka E, Duzova A, Bakkaloglu A, Kallinich T (2008) Disease severity in children and adolescents with Familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 68:246–248PubMedCrossRefGoogle Scholar
  14. 14.
    The WHOQOL Group (1998) Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28(3):551–558CrossRefGoogle Scholar
  15. 15.
    Pras E, Livneh A, Balow JE Jr, Kastner DL, Pras M, Langevitz P (1998) Clinical differences between North African and Iraqi Jews with Familial Mediterranean fever. Am J Med Genet 75(2):216–219PubMedCrossRefGoogle Scholar
  16. 16.
    Plebani M, De Toni S, Sanzari MC, Bernardi D, Stockreiter E (1998) The TEST 1 automated system: a new method for measuring the erythrocyte sedimentation rate. Am J Clin Pathol 110(3):334–340PubMedGoogle Scholar
  17. 17.
    Inal V, Kitapcioglu G, Karabulut G, Keser G, Kabasakal Y (2010) Evaluation of quality of life in relation to anxiety and depression in primary Sjogren’s syndrome. Mod Rheumatol 20(6):588–597. doi: 10.1007/s10165-010-0329-z PubMedCrossRefGoogle Scholar
  18. 18.
    Akvardar Y, Akdede BB, Ozerdem A, Eser E, Topkaya S, Alptekin K (2006) Assessment of quality of life with the WHOQOL-BREF in a group of Turkish psychiatric patients compared with diabetic and healthy subjects. Psychiatr Clin Neurosci 60(6):693–699. doi: 10.1111/j.1440-1819.2006.01584.x CrossRefGoogle Scholar
  19. 19.
    Eser E, Fidaner H, Fidaner C (1999) Psychometric properties of the WHOQOL-100 and WHOQOL-BREF. 3P Dergisi 7(ek 2):23–40Google Scholar
  20. 20.
    Neumann L, Buskila D (1997) Measuring the quality of life of women with fibromyalgia: a Hebrew version of the quality of life scale. J Musculoskelet Pain 5(1):5–17CrossRefGoogle Scholar
  21. 21.
    Flanagan J (1978) A research approach to improving our quality of life. Am Psychol 33(2):138–147CrossRefGoogle Scholar
  22. 22.
    Burckhardt C, Anderson K (2003) The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes 1:60PubMedCrossRefGoogle Scholar
  23. 23.
    Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A (2005) Evaluation of disease severity in Familial Mediterranean fever. Semin Arthr Rheum 35(1):57–64CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Arnd Giese
    • 1
    Email author
  • Mustafa Kurucay
    • 1
  • Levent Kilic
    • 2
  • Ahmet Örnek
    • 1
  • Süleyman Nahit Şendur
    • 3
  • Elke Lainka
    • 4
    • 5
  • Bernhard Ferdinand Henning
    • 1
  1. 1.Central Patient Admission Unit/Emergency Department, Marienhospital HerneRuhr-University BochumHerneGermany
  2. 2.Unit of Rheumatology, Department of Internal MedicineHacettepe UniversityAnkaraTurkey
  3. 3.Department of Internal MedicineHacettepe UniversityAnkaraTurkey
  4. 4.Department of PaediatricsUniversity Medical Centre EssenEssenGermany
  5. 5.AID-NET Autoinflammatory Disorders (AID) in Children: Genetics, Disease Mechanisms, Diagnostic Markers and Therapeutic TargetsEssenGermany

Personalised recommendations